August 4, 2009
The Therapeutic Goods Administration has approved broader access to Gardasil, which has been involved in a national immunisation program taking in females aged 12 to 26.
Developed by 2006 Australian of the Year Professor Ian Frazer, Gardasil offers protection against four strains of the Human Papilloma Virus.
Comment from Leslie
To the best of my knowledge and research – this age group was not tested in the trials. Women with weakened immune and endocrine systems because of age will be sujected to this vaccine with dire consequences.